CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
Galantamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01669538
NCT01669538Phase 2Completed
CompareCT.gov

Repurposing Cholinesterase Inhibitors for Smoking Cessation.

University of Pennsylvania·interventional·Posted Aug 21, 2012·Updated Feb 15, 2019

In Brief

A Phase 2 clinical trial evaluating Galantamine and Placebo for Tobacco Use Disorder. Completed, enrolled 98 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, placebo-controlled study to test whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI), National Center for Research Resources (NCRR), National Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 21, 2012
Enrollment StartAug 1, 2012
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.9 years ago

Interventions

Galantaminedrug

Placebodrug